Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular subtypes of high-grade serous ovarian cancer across racial groups and gene expression platforms.
Davidson NR, Barnard ME, Hippen AA, Campbell A, Johnson CE, Way GP, Dalley BK, Berchuck A, Salas LA, Peres LC, Marks JR, Schildkraut JM, Greene CS, Doherty JA. Davidson NR, et al. Among authors: peres lc. Cancer Epidemiol Biomarkers Prev. 2024 May 23. doi: 10.1158/1055-9965.EPI-24-0113. Online ahead of print. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 38780898
Racial and ethnic differences in epithelial ovarian cancer risk: an analysis from the Ovarian Cancer Association Consortium.
Meagher NS, White KK, Wilkens LR, Bandera EV, Berchuck A, Carney ME, Cramer DW, Cushing-Haugen KL, Jordan S, Kaufmann SH, Le ND, Pike MC, Riggan M, Qin B, Rothstein JH, Titus L, Winham SJ, Anton-Culver H, Doherty JA, Goode EL, Pearce CL, Risch HA, Aocs Group OBOT, Webb PM, Cook LS, Goodman MT, Harris HR, Le Marchand L, McGuire V, Pharoah PDP, Sarink D, Schildkraut JM, Sieh W, Terry KL, Thompson PJ, Whittemore AS, Wu AH, Peres LC, Merritt MA. Meagher NS, et al. Among authors: peres lc. Am J Epidemiol. 2024 May 21:kwae076. doi: 10.1093/aje/kwae076. Online ahead of print. Am J Epidemiol. 2024. PMID: 38775277
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD Jr, Lin Y. Afrough A, et al. Among authors: peres lc. Blood Cancer J. 2024 Apr 12;14(1):63. doi: 10.1038/s41408-024-00993-0. Blood Cancer J. 2024. PMID: 38609386 Free PMC article. No abstract available.
WITHDRAWN: Impact of spatial clustering of cytotoxic and tumor infiltrating lymphocytes on overall survival in women with high grade serous ovarian cancer.
Soupir AC, Townsend MK, Hathaway CA, Nguyen J, Moran Segura C, Saeed-Vafa D, Ospina OE, Peres LC, Conejo-Garcia JR, Terry KL, Tworoger SS, Fridley BL. Soupir AC, et al. Among authors: peres lc. medRxiv [Preprint]. 2024 Feb 28:2024.01.16.24301371. doi: 10.1101/2024.01.16.24301371. medRxiv. 2024. PMID: 38293174 Free PMC article. Preprint.
Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium.
Petrick JL, Joslin CE, Johnson CE, Camacho TF, Peres LC, Bandera EV, Barnard ME, Beeghly A, Bethea TN, Dempsey LF, Guertin K, Harris HR, Moorman PG, Myers ER, Ochs-Balcom HM, Rosenow W, Setiawan VW, Wu AH, Schildkraut JM, Rosenberg L. Petrick JL, et al. Among authors: peres lc. Br J Cancer. 2023 Dec;129(12):1956-1967. doi: 10.1038/s41416-023-02407-7. Epub 2023 Oct 21. Br J Cancer. 2023. PMID: 37865688
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini O, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri C, Anderson LD Jr, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees P, Khouri J, McGuirk J, Sidana S, Hansen DK, Patel K. Peres LC, et al. Blood Adv. 2024 Jan 9;8(1):251-259. doi: 10.1182/bloodadvances.2023010894. Blood Adv. 2024. PMID: 37855718 Free PMC article.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Hashmi H, et al. Among authors: peres lc. Haematologica. 2024 May 1;109(5):1514-1524. doi: 10.3324/haematol.2023.283888. Haematologica. 2024. PMID: 37855036 Free PMC article.
143 results